



## RESULTS OF 2025 ANNUAL STOCKHOLDERS MEETING

**14 May 2025** – Melbourne, Australia (**13 May 2025** – Minneapolis, MN United States) – **Imricor Medical Systems, Inc. (Company or Imricor) (ASX: IMR)** refers to the Annual Stockholders Meeting held today. The results of the meeting are set out in the attached document in accordance with ASX Listing Rule 3.13.2. All resolutions were decided and passed by way of a poll.

### ENDS

Authorised for release by Steve Wedan, Executive Chair, President, and CEO

#### Media and Investor Relations Contact:

Simon Hinsley  
Executive Director, NWR  
simon@nwrcommunications.com.au  
+61 401 909 653

Nick Corkill  
VP Corporate Strategy, Imricor  
nick.corkill@imricor.com  
+61 450 475 633

#### About Imricor

Imricor Medical Systems, Inc. (ASX:IMR) is striving to make interventional medical procedures better, safer, and more cost effective by making it possible for these procedures to be performed under real-time magnetic resonance imaging (MRI) guidance, rather than under x-ray fluoroscopy guidance, thus taking advantage of MRI's superior imaging capabilities.

#### Imricor's Products

Imricor is a pioneer and leader in developing MRI-compatible products for cardiac catheter ablation procedures, and believes it is the first company in the world to bring commercially viable and safe MRI-compatible products to the cardiac catheter ablation market.

The Vision-MR Ablation Catheter is the Company's prime product offering, specifically designed to work under real-time MRI guidance, with the intent of enabling higher success rates along with faster and safer treatment compared to conventional procedures using x-ray guided catheters. The Vision-MR Ablation Catheter has been approved in the European Union, the Kingdom of Saudi Arabia (KSA), and New Zealand with an indication for treating type 1 atrial flutter. Imricor intends to seek approval for expanded indications in the future. The Company is also pursuing the required regulatory approvals to place its key products on the market in the U.S. and the other Middle East countries.

The Company has also obtained approval within the EU and KSA for the sale of the Advantage-MR EP Recorder/Stimulator System and other consumable products, such as the Vision-MR Diagnostic Catheter (pending in KSA) and Vision-MR Dispersive Electrode.

Imricor sells its capital and consumable products to hospitals and clinics for use in Interventional Cardiac Magnetic Resonance Imaging (iCMR) labs, in which ablation procedures using the Vision-MR Ablation Catheter can be performed. An iCMR lab is an interventional lab that is fitted with MRI equipment for use in cardiac diagnostic and interventional procedures. The installation of iCMR labs is driven primarily by MRI equipment vendors working collaboratively with Imricor. Vendors such as Koninklijke Philips N.V., Siemens Healthcare GmbH, and GE HealthCare help to target certain sites and support the design and construction of iCMR labs for those sites.

#### Foreign Ownership Restrictions

Imricor's CHES Depositary Interests (**CDIs**) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (**Securities Act**) for offers which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. As a result of relying on the Regulation S exemption, the CDIs are 'restricted securities' under Rule 144 of the Securities Act. This means that you are unable to sell the CDIs into the US or to a US person for the foreseeable future except in very limited circumstances after the expiration of a restricted period, unless the re-sale of the CDIs is registered under the Securities Act or an exemption



is available. To enforce the above transfer restrictions, all CDIs issued bear a 'FOR US' designation on the Australian Securities Exchange (**ASX**). This designation restricts any CDIs from being sold on ASX to US persons. However, you are still able to freely transfer your CDIs on ASX to any person other than a US person. In addition, hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.

#### **Forward-Looking Statements**

This announcement contains or may contain forward-looking statements that are based on the Company's management's beliefs, assumptions and expectations and on information currently available to management. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These include, without limitation, EU commercial market acceptance and EU sales of our product as well as our expectations with respect to our ability to develop and commercialise new products. Management believes that these forward-looking statements are reasonable when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. Imricor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Imricor may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

## Results of meeting

Name of entity

Imricor Medical Systems, Inc.

ARBN

633 106 019

Date of meeting

14 May 2025 Australian time (13 May 2025 US time)

Resolutions voted on at the meeting					If decided by poll <sup>5</sup>					Proxies received <sup>6</sup>			
Resolution		Result <sup>2</sup>	Voting method <sup>3</sup>	If s250U applies <sup>4</sup>	Voted for		Voted against		Abstained	For	Against	Abstain	Discretion <sup>9</sup>
No <sup>1</sup>	Short description				Number	% <sup>7</sup>	Number	% <sup>8</sup>		Number	Number	Number	Number
1	Election of Class III Director – Mr Peter McGregor	Passed	Poll	N/A	104,438,575	98.71	-	-	1,370,217 (withheld)	103,782,956	-	1,370,217 (withheld)	-
2	Election of Class III Director – Dr Jeffrey Leighton	Passed	Poll	N/A	105,808,792	100.00	-	-	-	105,153,173	-	-	-
3	Approval of the 2019 Equity Incentive Plan and increase in reserved Shares	Passed	Poll	N/A	93,793,046	94.64	5,214,130	5.26	95,728	93,137,427	5,214,130	95,728	-
4a	Grant of Options to Mr Steve Wedan, Chief Executive Officer of the Company	Passed	Poll	N/A	93,820,646	94.67	5,281,658	5.33	600	93,165,027	5,281,658	600	-
4b	Grant of Options to Mr Steve Wedan, Chief Executive Officer of the Company	Passed	Poll	N/A	72,309,470	72.97	26,732,834	26.97	60,600	71,653,851	26,732,834	60,600	-
5	Grant of Restricted Stock Award to Mr Peter McGregor, Non-Executive Director of the Company	Passed	Poll	N/A	93,881,787	94.32	5,220,517	5.24	433,455	93,226,168	5,220,517	433,455	-
6	Grant of Restricted Stock Award to Ms Anita Messal, Non-Executive Director of the Company	Passed	Poll	N/A	93,881,787	94.73	5,220,517	5.27	600	93,226,168	5,220,517	600	-

7	Grant of Restricted Stock Award to Mr Mark Tibbles, Non-Executive Director of the Company	Passed	Poll	N/A	93,744,313	94.60	5,274,658	5.32	83,933	93,088,694	5,274,658	83,933	-
8	Ratification and approval of prior issue of CDIs under Placement	Passed	Poll	N/A	83,055,966	88.04	78,772	0.08	11,212,411	82,400,347	78,772	11,212,411	-
9	Ratification of the appointment of BDO USA, P.C. as independent registered public accounting firm	Passed	Poll	N/A	105,796,080	99.99	4,581	0.00	8,131	105,140,461	4,581	8,131	-

Resolutions proposed but not put to the meeting <sup>10</sup>		
No <sup>1</sup>	Short description	Reason(s) for not putting the resolution to the meeting

## Instructions:

- The resolution numbers in the tables above should match the resolution numbers in the notice of meeting.
- Insert "Passed" or "Not passed", as appropriate.
- Insert "Poll" or "Show of hands", as appropriate.
- Insert "1st strike", "2nd strike" or "N/A", as appropriate.
- Complete this section if the resolution was decided by a poll. Ignore this section if the resolution was decided by a show of hands.
- Complete this section for all resolutions, showing the number of valid proxies received and how the proxy was directed to vote on the resolution.
- Calculate this percentage as the number of votes cast for the resolution, divided by the total number of votes cast on the resolution. When summed with the percentage voted against the resolution, this should add to 100%.
- Calculate this percentage as the number of votes cast against the resolution, divided by the total number of votes cast on the resolution. When summed with the percentage voted for the resolution, this should add to 100%.
- "Discretion" means the proxy could vote on the resolution in their discretion.
- Delete this table if there were no resolutions proposed but not put to the meeting.
- Add or remove rows from each table to accommodate the number of resolutions proposed in the notice of meeting.
- Delete these instructions before submitting this form to ASX.
- See Guidance Note 35 *Security Holder Resolutions* for further guidance.